4-Hydroxytestosterone transdermal

Drug Profile

4-Hydroxytestosterone transdermal

Alternative Names: 4-hydroxy-testosterone; 4-OH-testosterone; 4-OHT - Curadis; CR 1477

Latest Information Update: 11 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Curadis
  • Developer Curadis; Swiss Group for Clinical Cancer Research
  • Class Anabolic steroids; Antineoplastics; Steroids; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists; Estrogen receptor alpha modulators; Estrogen receptor beta modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer

Most Recent Events

  • 26 Mar 2014 Curadis plans a phase I/II trial for Breast cancer (Late-stage disease) in Switzerland (NCT02067741)
  • 03 Mar 2014 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top